Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Lexicon Pharmaceuticals, Inc.    LXRX

LEXICON PHARMACEUTICALS, INC. (LXRX)
My previous session
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Lexicon Pharmaceuticals, Inc. : Lexicon Pharma to cut 45 percent jobs, CEO to leave

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/13/2014 | 12:57pm CEST

(Reuters) - Lexicon Pharmaceuticals Inc said its Chief Executive would leave and it would cut its workforce by about 45 percent, as it moves its focus away from drug discovery to completing the studies of its drugs in late-stage development.

Lexicon said it would cut 115 jobs, primarily positions in research and discovery to reduce costs.

"This transition increases Lexicon's financial strength and will enable the company to more effectively advance our key late-stage programs and to prepare for commercialization," CEO Arthur Sands said in a statement on Monday.

The company said it would focus mainly on its drugs to treat diabetes and carcinoid syndrome, a condition which affects some people with a rare cancerous tumor.

Lexicon said it expects to lower expenses by about $14 million, net of severance costs and some other charges, for the rest of 2014. It expects to save about $22 million annually.

The company had $151.2 million in cash and investments as of September 30 last year.

The company said Sands intends to develop a succession plan with the board to identify a new CEO, and will continue in his position until a successor is appointed.

The company is testing two other drugs in mid-stage trials to treat irritable bowel syndrome and rheumatoid arthritis. It also has a glaucoma drug in early-stage development.

Lexicon said last month its irritable bowel syndrome drug did not meet the main goal of a mid-stage study.

Lexicon shares, which lost about 15 percent of their value last year, closed at $2 on the Nasdaq on Friday.

(Reporting by Vrinda Manocha in Bangalore; Editing by Joyjeet Das)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LEXICON PHARMACEUTICALS, I
09/04LEXICON PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Crea..
AQ
08/30Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
GL
08/22UPDATE : Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
GL
08/22Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
GL
08/02Lexicon Pharmaceuticals Reports Second Quarter 2018 Financial Results and Pro..
AQ
07/31LEXICON PHARMACEUTICALS : to Present at Upcoming Investor Conference
AQ
07/30LEXICON PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
AQ
07/30LEXICON PHARMACEUTICALS, INC. : Results of Operations and Financial Condition (f..
AQ
07/30LEXICON : 2Q Earnings Snapshot
AQ
07/30Lexicon Pharmaceuticals Reports Second Quarter 2018 Financial Results and Pro..
GL
More news
News from SeekingAlpha
2015SEEKING ALPHA'S BIOTECH WEEKLY : A Gilead Victory, Celladon Crumbles, And More 
2015Lexicon Undervalued As It Approaches A Major Event 
2015Lexicon Pharmaceuticals' (LXRX) CEO Lonnel Coats on Q1 2015 Results - Earning.. 
2015Lexicon Pharmaceuticals EPS in-line, beats on revenue 
2015Lexicon Pharmaceuticals - A Diamond In The Rough? 
Financials ($)
Sales 2018 66,3 M
EBIT 2018 -132 M
Net income 2018 -145 M
Debt 2018 120 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 18,9x
EV / Sales 2019 6,06x
Capitalization 1 134 M
Chart LEXICON PHARMACEUTICALS, INC.
Duration : Period :
Lexicon Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 28,8 $
Spread / Average Target 168%
EPS Revisions
Managers
NameTitle
Lonnel Coats President, Chief Executive Officer & Director
Raymond Debbane Chairman
Jeffrey L. Wade CFO, EVP-Corporate & Administrative Affairs
Pablo Lapuerta Chief Medical Officer & Executive Vice President
Frank P. Palantoni Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LEXICON PHARMACEUTICALS, INC.12.10%1 134
GILEAD SCIENCES4.45%97 005
VERTEX PHARMACEUTICALS17.84%46 134
REGENERON PHARMACEUTICALS2.06%41 105
NEUROCRINE BIOSCIENCES, INC.51.32%10 877
GENMAB1.90%10 184